Daewoong Pharmaceutical said it has submitted a  request for a suspension of execution to the Seoul Central District Court on Wednesday regarding the judgment in a civil lawsuit against Medytox related to the theft of botulinum strain (BTX) strain.

Previously, the Seoul Central District Court ruled in favor of Medytox against Daewoong Pharmaceutical and Daewoong Co., including the prohibition of infringement of trade secrets, and ordered Daewoong to compensate for damages of 40 billion won ($31.6 million), turn over Daewoong's BTX strain to Medytox, and discard all finished BTX products made with the strain.

According to Daewoong Pharmaceutical, as a result of the recently disclosed verdict ruling, the court accepted the main facts for which Medytox, the plaintiff, had to prove with either objective evidence or indirect circumstantial facts.

"The court either ignored or unfairly judged Daewoong's refutation and valid suspicion," the company said.

Daewoong said it plans to make sure that there are no problems with the manufacturing and supply of Nabota, its BTX, with the submission of the application for suspension of enforcement against this ruling.

"The supply to U.S. and EU, sold by Evolus and AEON BioPharma, will also proceed normally as all rights are guaranteed through an agreement between the two companies and Medytox in the past," the company said. "As a result of the analysis of the ruling, we confirmed that it was an unfair judgment full of confirmation bias."

Therefore, through thorough truth-finding, the company will correct the misjudgment in the appeal court, it added.